Yongxiang Zheng - May 11, 2023 Form 4 Insider Report for NovaBay Pharmaceuticals, Inc. (NBY)

Role
Director
Signature
/s/ Justin Hall as attorney in fact for Yongxiang Zheng
Stock symbol
NBY
Transactions as of
May 11, 2023
Transactions value $
$0
Form type
4
Date filed
5/15/2023, 06:52 PM
Previous filing
May 13, 2022
Next filing
Jun 13, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NBY Common Stock Options Exercise +858 858 May 11, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NBY Restricted Stock Units Options Exercise $0 -858 -100% $0.00* 0 May 11, 2023 Common Stock 858 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On November 15, 2022, NovaBay Pharmaceuticals, Inc. effected a 1-for-35 reverse stock split of its common stock, which is reflected in the number of shares.
F2 Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vested on the one year anniversary of the date of grant.